Biosimilars in IBD: What Every Clinician Needs to Know

Area of Science:

• Gastroenterology
• Pharmacoeconomics
• Immunology

Background:

• Biologic therapies are essential for inflammatory bowel disease (IBD) management but are associated with high costs.
• Biosimilars, highly similar biologic products, are intended to reduce healthcare expenditures.
• Suboptimal uptake of biosimilars in IBD limits potential cost savings and access to treatment.

Purpose of the Study:

• To review the fundamental concepts of biosimilars.
• To identify currently available biosimilar products for IBD treatment.
• To explore resources that can facilitate the increased utilization of biosimilars in IBD care.

Main Methods:

• Literature review of biosimilar concepts and IBD treatment guidelines.
• Analysis of approved biosimilar products for IBD (infliximab, adalimumab, ustekinumab).
• Examination of reported barriers to biosimilar adoption and strategies for overcoming them.

Main Results:

• Biosimilars for infliximab, adalimumab, and ustekinumab are approved for IBD.
• Low uptake persists due to concerns regarding efficacy, safety, and market entry timelines.
• Evidence demonstrates comparable efficacy and safety profiles between biosimilars and reference biologics in IBD.

Conclusions:

• Biosimilars represent a valuable strategy to reduce biologic-related costs in IBD.
• Addressing clinician and patient concerns is crucial for enhancing biosimilar utilization.
• Collaborative efforts among stakeholders are necessary to maximize the benefits of biosimilars in IBD treatment.